- Home
- ADD vs IGC Comparison
ADD vs IGC Comparison
Compare ADD & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADD
- IGC
- Stock Information
- Founded
- ADD 2002
- IGC 2005
- Country
- ADD United States
- IGC United States
- Employees
- ADD N/A
- IGC N/A
- Industry
- ADD Engineering & Construction
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- ADD Consumer Discretionary
- IGC Health Care
- Exchange
- ADD Nasdaq
- IGC Nasdaq
- Market Cap
- ADD 33.8M
- IGC 23.8M
- IPO Year
- ADD N/A
- IGC N/A
- Fundamental
- Price
- ADD $1.32
- IGC $0.36
- Analyst Decision
- ADD
- IGC Strong Buy
- Analyst Count
- ADD 0
- IGC 2
- Target Price
- ADD N/A
- IGC $3.63
- AVG Volume (30 Days)
- ADD 487.0K
- IGC 385.2K
- Earning Date
- ADD 06-01-2024
- IGC 11-11-2024
- Dividend Yield
- ADD N/A
- IGC N/A
- EPS Growth
- ADD N/A
- IGC N/A
- EPS
- ADD N/A
- IGC N/A
- Revenue
- ADD $1,060,442.00
- IGC $1,062,000.00
- Revenue This Year
- ADD N/A
- IGC $0.59
- Revenue Next Year
- ADD N/A
- IGC $13.01
- P/E Ratio
- ADD N/A
- IGC N/A
- Revenue Growth
- ADD N/A
- IGC N/A
- 52 Week Low
- ADD $0.17
- IGC $0.25
- 52 Week High
- ADD $1.86
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- ADD 77.70
- IGC 40.58
- Support Level
- ADD $0.57
- IGC $0.35
- Resistance Level
- ADD $1.49
- IGC $0.39
- Average True Range (ATR)
- ADD 0.21
- IGC 0.02
- MACD
- ADD 0.07
- IGC 0.00
- Stochastic Oscillator
- ADD 96.25
- IGC 50.00
About ADD Color Star Technology Co. Ltd.
Color Star Technology Co Ltd is an entertainment technology and education company providing online and offline music education. The curriculum developed by the company includes music, sports, animation, painting and calligraphy, film and television, and life skills, covering various aspects of entertainment, sports, and culture.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.